Importantly, MATE1 but not OCT1 expression is reduced in total bone marrow cells of imatinib-non-responding CML patients compared with imatinib-responding patients, indicating that MATE1 but not OCT1 determines the therapeutic success of imatinib. Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.